CPG for Eating Disorders

Summary of the EvidenceCPG 30There is insufficient evidence to determine that antiemetics (ondansetron) aremore or less effective when compared to placebo (2 RCTs; N=37; Faris, 1998 317 ,2000 317 ).Recommendations(See recommendations 9.GPH.1. to 9.GPH.6.)9.15.1.2. What is the safety of ondansetron in patients with BN?The answer is based on the NICE CPG (2004) 30 , on the high-quality SRSE (1++)elaborated by the AHRQ of the US (2006) 31 and on a more recently published high-quality SRSE(1++) conducted by Shapiro, et al. (2007) 211 . The updated search has no identified any newevidence. The study is briefly described in question 9.15.1.1.Scientific EvidenceIn an RCT (Faris, 2000) 317 , one participant dropped out of treatment in the ondansetrongroup and there were no dropouts in the placebo group. No adverse effects werereported.RCT1++Summary of the EvidenceCPG 30There is insufficient evidence to determine that antiemetics (ondansetron) aremore or less acceptable vs. placebo (2 RCTs; N=37; Faris, 1998 317 , 2000 317 ).Recommendations(See recommendations 9.GPH.1. to 9.GPH.6.)157CLINICAL PRACTICE GUIDELINE FOR EATING DISORDERS